Pfizer has recently completed a $10 billion acquisition of Metsera, a significant move that has been met with varying reactions by industry analysts. The company also intends to sell its stake in BioNTech, its pandemic vaccine partner. The focus clearly is on surgical expansions and contractions to their portfolio. While some investors are concerned about the potentially overpriced Metsera acquisition and a potential patent cliff, others see strong potential growth in Pfizer’s portfolio and hence a good value buying opportunity. High dividend yield adds to its attractiveness for long-term investors. Uncertainty around the stock has increased after mixed third quarter results and the consequent revaluation of the BioNTech stake. However, Pfizer’s stocks rose as Metsera shareholders approved the $10B acquisition, albeit Pfizer's stocks slipped again in the premarket. Pfizer’s management remains optimistic and has raised earnings outlook despite facing some headwinds in the near term.
Pfizer Stocks News Analytics from Mon, 09 Jun 2025 07:00:00 GMT to Sat, 15 Nov 2025 17:18:39 GMT -
